These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 1540212

  • 1. Cellular uptake and tubulin binding properties of four Vinca alkaloids.
    Singer WD, Himes RH.
    Biochem Pharmacol; 1992 Feb 04; 43(3):545-51. PubMed ID: 1540212
    [Abstract] [Full Text] [Related]

  • 2. Use of snail neurons in developing quantitative ultrastructural parameters for neurotoxic side effects of Vinca antitumor agents.
    Müller LJ, Moorer-van Delft CM, Zijl R, Roubos EW.
    Cancer Res; 1990 Mar 15; 50(6):1924-8. PubMed ID: 2407348
    [Abstract] [Full Text] [Related]

  • 3. Uptake of Vinca alkaloids into mammalian nerve and its subcellular components.
    Iqbal Z, Ochs S.
    J Neurochem; 1980 Jan 15; 34(1):59-68. PubMed ID: 6161213
    [Abstract] [Full Text] [Related]

  • 4. Relationship between the cellular accumulation and the cytotoxicity of S12363, a new Vinca alkaloid derivative.
    Pierré A, Pérez V, Léonce S, Boutin JA, Saint-Dizier D, Hautefaye P, Lavielle G, Atassi G.
    Cancer Chemother Pharmacol; 1992 Jan 15; 29(5):367-74. PubMed ID: 1551175
    [Abstract] [Full Text] [Related]

  • 5. Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.
    Natsume T, Watanabe J, Tamaoki S, Fujio N, Miyasaka K, Kobayashi M.
    Jpn J Cancer Res; 2000 Jul 15; 91(7):737-47. PubMed ID: 10920282
    [Abstract] [Full Text] [Related]

  • 6. Block of axoplasmic transport in vitro by vinca alkaloids.
    Chan SY, Worth R, Ochs S.
    J Neurobiol; 1980 May 15; 11(3):251-64. PubMed ID: 6156229
    [Abstract] [Full Text] [Related]

  • 7. Relationship between binding affinity, retention and sensitivity of human rhabdomyosarcoma xenografts to Vinca alkaloids.
    Houghton JA, Williams LG, Dodge RK, George SL, Hazelton BJ, Houghton PJ.
    Biochem Pharmacol; 1987 Jan 01; 36(1):81-8. PubMed ID: 3541941
    [Abstract] [Full Text] [Related]

  • 8. Pharmacological properties of a new alpha-aminophosphonic acid derivative of vinblastine.
    Pierré A, Lavielle G, Hautefaye P, Seurre G, Leonce S, Saint-Dizier D, Boutin JA, Cudennec CA.
    Anticancer Res; 1990 Jan 01; 10(1):139-44. PubMed ID: 2334119
    [Abstract] [Full Text] [Related]

  • 9. Theoretical insight into the structural mechanism for the binding of vinblastine with tubulin.
    Chi S, Xie W, Zhang J, Xu S.
    J Biomol Struct Dyn; 2015 Jan 01; 33(10):2234-54. PubMed ID: 25588192
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro.
    Jordan MA, Himes RH, Wilson L.
    Cancer Res; 1985 Jun 01; 45(6):2741-7. PubMed ID: 3986806
    [Abstract] [Full Text] [Related]

  • 11. Factors governing the modulation of vinca-alkaloid resistance in doxorubicin-resistant cells by the calmodulin inhibitor trifluoperazine.
    Ganapathi R, Grabowski D, Schmidt H.
    Biochem Pharmacol; 1986 Feb 15; 35(4):673-8. PubMed ID: 3947398
    [Abstract] [Full Text] [Related]

  • 12. Vindesine: a new vinca alkaloid.
    Bayssas M, Gouveia J, de Vassal F, Misset JL, Schwarzenberg L, Ribaud P, Musset M, Jasmin C, Hayat M, Mathé G.
    Recent Results Cancer Res; 1980 Feb 15; 74():91-7. PubMed ID: 7003662
    [Abstract] [Full Text] [Related]

  • 13. Positive interaction of bisbenzylisoquinoline alkaloid, cepharanthin, with vinca alkaloid agents against human tumors.
    Ono M, Tanaka N.
    In Vivo; 1997 Feb 15; 11(3):233-41. PubMed ID: 9239517
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Differential involvement of glutathione S-transferase mu 1 and multidrug resistance protein 1 in melanoma acquired resistance to vinca alkaloids.
    Attaoua C, Vincent LA, Abdel Jaoued A, Hadj-Kaddour K, Baï Q, De Vos J, Vian L, Cuq P.
    Fundam Clin Pharmacol; 2015 Feb 15; 29(1):62-71. PubMed ID: 25283245
    [Abstract] [Full Text] [Related]

  • 16. Growth inhibitory activity of S12363, a novel vinca alkaloid derivative on human melanoma cell lines.
    Tolis C, Photiou A, Camplejohn RS, Retsas S.
    Anticancer Res; 1993 Feb 15; 13(1):161-6. PubMed ID: 8476208
    [Abstract] [Full Text] [Related]

  • 17. Vinblastine, Vincristine and Vindesine: anti-invasive effect on MO4 mouse fibrosarcoma cells in vitro.
    Mareel MM, Storme GA, De Bruyne GK, Van Cauwenberge RM.
    Eur J Cancer Clin Oncol; 1982 Feb 15; 18(2):199-210. PubMed ID: 7201395
    [Abstract] [Full Text] [Related]

  • 18. Antitumor activities of harringtonine and homoharringtonine, cephalotaxus alkaloids which are active principles from plant by intraperitoneal and oral administration.
    Takeda S, Yajima N, Kitazato K, Unemi N.
    J Pharmacobiodyn; 1982 Oct 15; 5(10):841-7. PubMed ID: 7161711
    [Abstract] [Full Text] [Related]

  • 19. Markedly decreased binding of vincristine to tubulin in vinca alkaloid-resistant Chinese hamster cells is associated with selective overexpression of alpha and beta tubulin isoforms.
    Sirotnak FM, Danenberg KD, Chen J, Fritz F, Danenberg PV.
    Biochem Biophys Res Commun; 2000 Mar 05; 269(1):21-4. PubMed ID: 10694470
    [Abstract] [Full Text] [Related]

  • 20. Lysosomes and unfolded protein response, determinants of differential resistance of melanoma cells to vinca alkaloids.
    Vincent LA, Attaoua C, Bellis M, Rozkydalova L, Hadj-Kaddour K, Vian L, Cuq P.
    Fundam Clin Pharmacol; 2015 Apr 05; 29(2):164-77. PubMed ID: 25601431
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.